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Abstract
Local activation of cortisol in hormone target tissues is a major
determinant of glucocorticoid effect. Disorders in this periph-
eral cortisol metabolism play an important role in the develop-
ment of metabolic diseases, such as obesity or type 2 diabetes
mellitus. Hence, dietary factors inﬂuencing the activity of the
involved enzymes can have major impacts on the risk of the
above diseases. Resveratrol and epigallocatechin gallate
(EGCG), two natural polyphenols found in several nutriments
and in green tea, respectively, are well-known for their antiobe-
sity and antidiabetic activities. EGCG has been shown to inter-
fere with microsomal cortisol production through decreasing
the luminal NADPH:NADP+ ratio. The aim of this study was to
clarify if resveratrol also induces such a redox shift or causes
any direct enzyme inhibition that inﬂuences local cortisol pro-
duction. Cortisone–cortisol conversions and changes in NADPH
levels were monitored in rat liver microsomal vesicles. Cortisol
production was inhibited by resveratrol in a concentration
dependent manner while the intrinsic reducing and oxidizing
capacity as well as the NADPH level inside the ER-derived vesi-
cles remained unaffected. Activity measurements performed in
permeabilized microsomes conﬁrmed that resveratrol, unlike
EGCG, inhibits 11β-hydroxysteroid dehydrogenase type
1 directly. Long-term moderation of pre-receptor cortisol pro-
duction likely contributes to the beneﬁcial health effects of both
polyphenols. © 2018 BioFactors, 45(2):236–243, 2019
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1. Introduction
Glucocorticoids play a central role in several physiological pro-
cesses including regulation of salt-water balance and interme-
diary metabolism, immune, and anti-inﬂammatory responses,
reproductive processes, control of blood pressure, and mental
functions [1]. Precisely regulated levels of the major stress hor-
mone cortisol are essential for adapting to physical and emo-
tional stress, including prolonged starvation [2]. Cortisol
synthesis and secretion, adjusted to the nutrient supply and
energy demands are fundamentally controlled by the
hypothalamic–pituitary–adrenal axis. However, the activity of
the hormone is also regulated at a pre-receptor level. Type
1 11β-hydroxysteroid dehydrogenase (11βHSD1) is an NADP(H)-
dependent enzyme localized in the lumen of the endoplasmic
reticulum (ER) in glucocorticoid target tissues (liver, skeletal
muscle and adipose tissue). It modulates glucocorticoid
Abbreviations: 11βHSD1, Type 1 11β-hydroxysteroid dehydrogenase;
11βHSD2, Type 2 11β-hydroxysteroid dehydrogenase; EGCG, epigallocate-
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receptor activation by producing cortisol from its inactive pro-
hormone cortisone [3,4]. The NADPH cofactor for the reaction
is provided by hexose 6-phosphate dehydrogenase (H6PD) [5],
which is colocalized with 11βHSD1 in the ER. The substrate of
H6PD, glucose 6-phosphate enters the ER lumen through a
selective transporter glucose 6-phosphate translocase (G6PT)
[6]. Therefore, the pre-receptor cortisol production is due to a
concerted action of the G6PT-H6PD-11βHSD1 triad using a
luminal NADP+-NADPH pool, and it is fueled by a hexose 6-P
supply from the cytosol.
In the past few years, peripheral cortisol effect has been
proven to be one of the important factors in the pathomechan-
ism of the metabolic syndrome and type 2 diabetes mellitus [7].
The role of H6PD and 11βHSD1 in these obesity-related meta-
bolic diseases is supported by in vivo studies using transgenic
and knockout animals [8–10]. It is therefore evident that dietary
factors or medicines inﬂuencing the activity of these enzymes
may have a major impact on the development of these meta-
bolic disorders [11]. The G6PT-H6PD-11βHSD1 triad is a possi-
ble molecular target of anti-diabetic nutrition factors
(e.g., active substances of green tea, red wine, chocolate etc.) of
well-known beneﬁcial health effects [12,13].
Resveratrol (3, 5, 40-trihydroxy-stilbene) is a polyphenolic
ingredient of a great variety of food (mostly grape, red wine,
blueberry, peanuts, dark chocolate etc.). The biological actions
of resveratrol received an increasing scientiﬁc interest in the
past two decades, and a large amount of data supports its vari-
ous beneﬁcial health effects (for a review see [14]), including its
anti-diabetic property [15,16]. In diabetic rat model, the poly-
phenol reduces blood glucose level by enhancing the cellular
uptake of glucose and improving insulin action [17], thus res-
veratrol improves glucose tolerance while decreasing insulin
resistance [18].
Evidence has been presented that the tea ﬂavanol
epigallocatechin-3-gallate (EGCG) can inﬂuence pre-receptor
cortisol metabolism by causing an oxidative shift in the NADPH-
NADP+ pool of the ER [12]. The aim of the present study was to
elucidate whether resveratrol affects hepatic microsomal corti-
sol production through a similar mechanism. The effect of res-
veratrol on the G6PT-H6PD-11βHSD1 triad was investigated by
using intact and permeabilized rat liver microsomes.
2. Materials and methods
2.1. Materials
Alamethicin, cortisone, cortisol, epigallocatechin-3-gallate (EGCG),
G6P, metyrapone, NADP+, NADPH, 4-morpholinepropanesulfonic
acid (MOPS) and resveratrol were purchased from Sigma Chemical
Co. (St. Louis, MO). All other reagents and solvents were of analyti-
cal grade.
2.2. Preparation of rat liver microsomes
Rat liver microsomes were prepared from male Wistar rats
(200–250 g body weights) using fractional centrifugation [19].
Microsomes resuspended in MOPS-KCl buffer (100 mM KCl,
20 mM NaCl, 1 mM MgCl2, and 20 mM MOPS, pH 7.2) were rap-
idly frozen and stored in liquid N2 until used. Intactness of
microsomal vesicles was checked by measuring the latency of
mannose 6-phosphatase activity [20], which was greater than
92% in all the preparations employed. Protein concentration of
the microsomes was determined with Bio-Rad protein assay
solution using bovine serum albumin as a standard according
to the manufacturer’s instructions.
2.3. Microsomal cortisone-cortisol conversion
G6P-driven reduction of cortisone to cortisol (i.e., the overall
activity of the G6PT-H6PD-11βHSD1 triad) was measured by
incubating intact microsomes (0.5 mg/ml protein concentration)
in MOPS-KCl buffer with 5 μM cortisone and 50 μM G6P in a
ﬁnal volume of 150 μl at 37 C for 30 min. The activity of
11βHSD1 alone was assessed directly by measuring NADP+-
driven cortisol oxidation under similar conditions after pre-
treatment of microsomes with the pore-forming alamethicin
(0.1 mg/mg protein). These permeabilized vesicles (0.5 mg/ml
protein) were incubated in MOPS-KCl buffer containing 5 μM
cortisol and 50 μM NADP+ in a ﬁnal volume of 150 μl at 37 C
for 30 min. In either case, the reaction was terminated with
150 μl ice-cold methanol, and the samples were stored at
−20 C until HPLC analysis of cortisone and cortisol contents.
2.4. Fluorimetric detection of NADPH, measurement of
H6PD, and 11βHSD1 activities
NADPH content of intact microsomal vesicles was monitored by
continuous spectroﬂuorimetry using a Cary Eclipse spectroﬂuo-
rimeter (Varian, Woburn, MA) at 1 mg/ml protein concentration
in MOPS-KCl buffer at 22 C temperature. Oxidation and reduc-
tion of the luminal pyridine nucleotide pool was induced by
metyrapone (5 μM) and G6P (100 μM), respectively. EGCG and
resveratrol were administered at 100 μM concentration.
Changes in NADPH-speciﬁc ﬂuorescence were detected at
340 nm excitation and 460 nm emission wavelengths. When
resveratrol was used, the interference was minimized by setting
350 and 520 nm wavelengths.
H6PD activity was assessed by real-time ﬂuorimetric detec-
tion of NADPH production. Intact microsomes (1 mg/ml protein)
were incubated in a ﬂuorimetric cuvette in MOPS-KCl buffer
containing 2 mM NADP+ and 100 μM G6P at 37 C. The reaction
was initiated after recording a stable baseline by adding ala-
methicin (0.1 mg/mg protein) to eliminate the membrane bar-
rier and thus allow free access of the substrates to the
intraluminal enzyme of latent activity. 11βHSD1 activity was
measured similarly using cortisol (100 μM) as a substrate
instead of G6P in the incubation medium. NADPH standard
(10 μM) was added for calibration at the end of each ﬂuorimet-
ric detection in both cases.
2.5. Endogenous reducing/oxidizing capacity of the
microsomal vesicles
Intrinsic cortisone reducing or cortisol oxidizing capacity of the
microsomes was analyzed by incubating intact microsomal ves-
icles (0.5 mg/ml protein concentration) in MOPS-KCl buffer at
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37 C for 3 h in the presence of 10 μM cortisone or cortisol,
respectively. The reactions were terminated by adding equal
volume of ice-cold methanol. Samples were stored at −20 C
until HPLC analysis of cortisone and cortisol contents.
2.6. HPLC analysis
The methanol-treated samples were centrifuged (20,000 x g for
10 min at 4 C) and the protein-free supernatants were ana-
lyzed to measure cortisone and cortisol simultaneously. Com-
pounds were separated by HPLC (Alliance 2690; Waters Corp.,
Milford, MA) in a Nucleosil 100 C18 column (5 μm, 25 x 0.46)
(Teknokroma, Barcelona, Spain) with isocratic methanol–water
(58:42, vol/vol) at 0.7 ml/min ﬂow rate; and the absorbance in
the eluate was detected at 245 nm wavelength (Waters Dual λ
Absorbance Detector 2487). Retention times of cortisone and
cortisol were determined by injecting 10 μM standards.
2.7. Statistical analysis
Experiments were performed in triplicates, with each of the
values of a single set of experiments corresponding to the mean
of a minimum of 2–3 determinations. Data are presented as
means + standard deviation (SD). The results were analyzed by
one-way ANOVA and Tukey–Kramer Multiple Comparison Test
using GraphPad Prism® software. A P value below 0.01 or
0.0001 (as indicated in ﬁgure captions) was considered as a sig-
niﬁcant difference.
3. Results
3.1. Inhibition of microsomal cortisol production by
resveratrol
Effect of resveratrol on the overall activity of the G6PT-H6PD-
11βHSD1 triad of the ER was tested ﬁrst by using intact micro-
somal vesicles. The rate of cortisol production was determined
by incubating the microsomes (0.5 mg/mL) at 37 C for 30 min
in MOPS-KCl buffer supplemented with substrates: cortisone
(10 μM) and glucose-6-phosphate (50 μM). Cortisol production
was inhibited signiﬁcantly by resveratrol when administered
above 1 μM levels. The effect was concentration-dependent,
and a more than 50% decrease in the activity was achieved by
resveratrol at 100 μM (Fig. 1). This effectiveness was well-
comparable with that of the green tea ﬂavanol EGCG, which is
a known natural inhibitor of the cortisone reducing machinery,
and hence it was used as a positive control in our experi-
ments (Fig. 1).
3.2. Luminal pyridine dinucleotide redox status
The observed inhibition of cortisol production can be due to a
direct inhibition of the enzymes involved, or – as demonstrated
earlier in case of EGCG – to an oxidative shift in the redox state
of microsomal pyridine dinucleotides. The possible change in
NADPH content of the ER vesicles can be assessed directly by
ﬂuorimetry. Luminal NADPH can be detected as a stable ﬂuo-
rescent baseline in intact microsomal vesicles, and this ﬂuores-
cence can be efﬁciently depressed by the addition of cortisone,
metyrapone or EGCG. The phenomenon reﬂects the oxidation of
NADPH to NADP+ as evidenced by the partial recovery of the
signal upon addition of G6P (Fig. 2, upper traces). In contrast,
addition of resveratrol, even at high (100 μM) concentration,
did not decrease the level of NADPH. A small increase in ﬂuo-
rescence was seen, which might be due to an optical interfer-
ence. However, the subsequent addition of G6P did not cause
any further increase in the signal, which clearly shows the lack
of resveratrol-induced oxidation of intravesicular NADPH to
NADP+ (Fig. 2, bottom trace).
Luminal NADP+ and NADPH levels can also be investigated
indirectly by measuring the endogenous reducing and oxidizing
capacities, that is, the ability of the vesicles alone to intercon-
vert cortisone and cortisol. This approach exploits the luminal
11βHSD1 activity, which is driven only by the intrinsic NADPH
or NADP+ resources in the lack of any added substrates that
would provide with reducing or oxidative power. Intact micro-
somes were incubated with either cortisone or cortisol and the
rate of cortisol or cortisone production (driven merely by
endogenous reducing or oxidizing power) was measured by
HPLC. This approach was successfully applied earlier to dem-
onstrate the redox shift caused by EGCG [12] or the effects of
nutritional state in vivo [21]. In a striking contrast to EGCG,
which abolished the reducing capacity while remarkably
increased the oxidizing capacity of rat liver microsomes [12],
resveratrol caused an almost equally small (10–20%) decrease
in both converting capacities (Fig. 3), which indicates an inhibi-
tion of 11βHSD1 rather than an alteration of NADPH:NADP+
ratio in any direction. The apparently higher inhibition of oxi-
dizing capacity in case of 100 μM resveratrol is most likely due
to the general antioxidant property of the substance, which
inhibits all natural oxidative processes, during the 2 h’
experiment.
FIG 1
Microsomal cortisol production. Intact rat liver micro-
somal vesicles (0.5 mg/mL) were incubated at 37C
for 30 min in MOPS-KCl buffer supplemented with
cortisone (10 μM), glucose 6-phosphate (50 μM) and
EGCG or resveratrol (Rsv) at different concentrations
as indicated. The amount of cortisol was then mea-
sured with HPLC. The rate of cortisol production was
calculated and shown as mean  SD, n = 3, ***P <
0.0001 versus control.
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3.3. H6PD and 11βHSD1 activities
As it became evident that the obstruction of microsomal cortisol
production is not due to a redox shift in the intravesicular
NADPH:NADP+ pool, the putative inhibition of two enzymes
involved in the process was tested. Permeabilization of the
microsomal membranes by the pore forming antibiotic ala-
methicin (0.1 mg/mg protein) uncouples H6PD and 11βHSD1
activities, and it provides the enzymes with free access to pyri-
dine dinucleotide cofactors added to the incubation medium.
Therefore, the activities of H6PD and 11βHSD1 can be mea-
sured separately in permeabilized microsomes by real time
ﬂuorescent detection of G6P- or cortisol-dependent NADPH
production.
Addition of the substrate, G6P or cortisol to intact rat liver
microsomes in the presence of NADP+ did not trigger the forma-
tion of NADPH because the activity of both luminal enzymes,
H6PD and 11βHSD1 is rendered completely latent by imperme-
ability of the ER membrane to pyridine dinucleotides (Figs. 4
FIG 3
Endogenous reducing and oxidizing capacities of liver
microsomes. Intrinsic cortisone reducing or cortisol
oxidizing capacity of microsomal vesicles was ana-
lyzed by incubating intact microsomes (3 mg/mL pro-
tein concentration) in MOPS-KCl buffer at 37 C for 2
h in the presence of 10 μM cortisone or cortisol,
respectively. The amounts of cortisol and cortisone
were measured with HPLC. Data are expressed as %
of the control values (cortisone reduction: 0.16  0.04
pmol/min/mg protein; cortisol oxidation: 0.22  0.01
pmol/min/mg protein) and shown as mean  SD, n =
3, *P < 0.01, ***P < 0.0001 versus control.
FIG 2
Modulation of NADPH level in the microsomal lumen.
Endogenous NADPH content of intact microsomal
vesicles was monitored at 1 mg/ml protein concentra-
tion in MOPS-KCl buffer by continuous ﬂuorescence
detection. Oxidation of the luminal pyridine dinucleo-
tide pool was observed after addition of 10 μM corti-
sone, 10 μM metyrapone, or 100 μM EGCG, and it
could be counteracted by the administration of 100
μM G6P in all cases. Addition of 100 μM resveratrol
did not lower the ﬂuorescent, while the subsequent
addition of G6P did not increase the signal of NADPH.
Typical traces of three independent experiments are
shown.
FIG 4
Hexose-6-phosphate dehydrogenase activity. Intact
rat liver microsomes (1 mg/mL protein) were incu-
bated in a ﬂuorimetric cuvette in MOPS-KCl buffer at
37C in the absence (top trace) or presence of 100 μM
resveratrol (bottom trace), and the ﬂuorescence of
NADPH was recorded continuously. After addition of
the substrates (2 mM NADP+ and 100 μM G6P), H6PD
activity was initiated by permeabilizing the mem-
branes with alamethicin (0.1 mg/mg protein). Detec-
tions were ﬁnished with the addition of NADPH
standard (10 μM). Typical traces of three independent
experiments are shown.
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and 5). The lack of G6P- and cortisol-dependent NADPH pro-
duction in intact microsomes provides additional evidence for
membrane integrity and for the absence of potentially interfer-
ing extravesicular activities in the microsome preparation. A
linear increase in the ﬂuorescent signal, which corresponds to
an H6PD or 11βHSD1-mediated NADPH generation started as
soon as the membranes were permeabilized by alamethicin.
H6PD activity was not affected signiﬁcantly by resveratrol
(4.62  0.18 vs. 4.00  0.39 nmol/min/mg protein in control
and treated microsomes, respectively) (Fig. 4), while 11βHSD1
activity was inhibited in a concentration dependent manner
(0.83  0.15, 0.37  0.09 and 0.18  0.04 nmol/min/mg protein
in cases of 10, 50, and 100 μM resveratrol, respectively,
vs. 0.82  0.19 nmol/min/mg protein as control) (Fig. 5). This
effect was also conﬁrmed in different conditions by HPLC mea-
surement of cortisol-to-cortisone conversion in permeabilized
microsomes (Fig. 6). In line with the ﬂuorimetric experiments, a
remarkable and concentration-dependent inhibition of
11βHSD1 activity was observed. In permeabilized microsomes
at close to physiological NADP+ levels, the effect of resveratrol
was signiﬁcant already at 10 μM concentration, and 11βHSD1
activity was almost abolished when the polyphenol was admin-
istered at 100 μM concentration.
4. Discussion
Obesity is a growing medical problem: the worldwide preva-
lence nearly tripled between 1975 and 2016 (in 2016, more
than 1.9 billion adults were overweight, 650 million of whom
were clinically obese) [22]. Obesity is an established risk factor
for type 2 diabetes mellitus and a central component of the
metabolic syndrome. Therefore, the increasing prevalence of
obesity is being paralleled by similar increases in the number of
persons with the above diseases [23]. Hence, studies on antio-
besity and antidiabetic agents in basic and applied research
have received a growing attention in the past decades. The epi-
demic is still growing not only in developed, but also in develop-
ing countries, so new strategies are called for.
Results of both in vitro and in vivo studies show that the
complex metabolism of the major stress hormone cortisol plays
FIG 6
Cortisol oxidation in permeabilized microso-
mes11βHSD1 activity was assessed separately on the
basis of cortisol-to-cortisone conversion. Microsomal
vesicles (0.5 mg/mL protein) permeabilized with ala-
methicin (0.1 mg/mg protein) were incubated at 37C
for 30 min in MOPS-KCl buffer supplemented with
cortisol (5 μM), NADP+ (50 μM) and resveratrol in dif-
ferent concentrations as indicated. The amount of
cortisone was then measured with HPLC. The rate of
cortisone production was calculated and shown as
mean  SD, n = 3, ***P < 0.0001 versus control.
FIG 5
11β-Hydroxysteroid dehydrogenase type 1 activity.
Intact microsomes (1 mg/mL protein) were incubated
in a ﬂuorimetric cuvette in MOPS-KCl buffer at 37C
in the absence (trace A) or presence of 10 μM (trace
B), 50 μM (trace C), or 100 μM resveratrol (trace D),
and the ﬂuorescence of NADPH was recorded contin-
uously. After addition of the substrates (2 mM NADP+
and 100 μM cortisol), 11βHSD1 activity was initiated
by permeabilizing the membranes with alamethicin
(0.1 mg/mg protein). Detections were ﬁnished with
the addition of NADPH standard (10 μM). Typical
traces of three independent experiments are shown
on the top panel, while the calculated enzyme activi-
ties are demonstrated as mean  SD, n = 3, ***P <
0.0001 versus control on the bottom panel.
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an important role in the pathomechanism of obesity-related
metabolic disorders [7]. Inﬂuencing the involved enzyme activi-
ties is, therefore, considered as a novel strategy for the preven-
tion or treatment of these diseases [24]. As mentioned before,
precisely regulated levels of cortisol are essential for adapting
to stress, including prolonged starvation. Besides its synthesis
and secretion controlled by the hypothalamic–pituitary–adrenal
axis, the activity of the hormone is also regulated at a pre-
receptor level by 11β-hydroxysteroid dehydrogenase enzymes,
which interconvert the active hormone cortisol and its inactive
prohormone cortisone [25] i.e., they enhance or diminish the
local hormone effects. The enzyme has two isoforms of distinct
physiological functions in humans, which differ from each other
in tissue speciﬁcity, intracellular localization and cofactor
demand: type 1 (11βHSD1) and type 2 (11βHSD2) [26,27].
11βHSD2, a cytoplasmic NAD-dependent enzyme inactivates
cortisol in mineralocorticoid target tissues (kidney, colon and
salivary glands) to protect the non-selective aldosterone recep-
tor from cortisol excess [28]. In contrast, 11βHSD1, which is an
NADP(H)-dependent enzyme localized in the lumen of the endo-
plasmic reticulum (ER) in glucocorticoid target tissues (liver,
skeletal muscle and adipose tissue), modulates glucocorticoid
receptor activation by interconverting cortisol and cortisone
predominantly toward the production of the active hormone
[3,4]. This tissue-speciﬁc local cortisol metabolism is largely
responsible for the peripheral cortisol effects without remark-
ably altering the serum hormone levels: the amount of locally
produced hormone can reach 25% of that of the newly synthe-
tized cortisol. The liver is responsible for roughly one third and
visceral adipose tissue for nearly two thirds of this pre-receptor
cortisol production [29]. This system is fueled by glucose
6-phosphate or fructose 6-phosphate from the cytosol [30], and
it provides a means of nutrient sensing by linking hexose
6-phosphate supply to glucocorticoid activity [31]. It has been
demonstrated that hepatic ER luminal NADPH level and micro-
somal cortisone reducing capacity are largely determined by
the nutritional status (starvation vs. fed state) in rats [21],
which further supports the putative role of local cortisol over-
production in obesity-related conditions.
As the repression of peripheral cortisol effect is beneﬁcial
in obesity and insulin resistance, research has focused on spe-
ciﬁc inhibition of 11βHSD1, the isoform that predominantly pro-
duces the active hormone. Overexpression of the enzyme in
adipose tissue leads to metabolic syndrome in mice [32], while
hepatic overexpression causes similar symptoms without obe-
sity [8]. In contrast, 11βHSD1 knockout mice display fasting
hypoglycemia, improved lipid and lipoprotein proﬁle, insulin
sensitivity, and glucose tolerance [10,11]. They were also found
to resist hyperglycemia, due to attenuated gluconeogenic
responses [9,11]. Knocking out the enzyme H6PD in mice leads
to similar metabolic effects [9,33].
Natural polyphenols, such as EGCG and resveratrol are
well-known anti-obesity and anti-diabetic agents; however, the
molecular mechanisms leading to these effects are not yet fully
explained. We investigated the effect of EGCG on pre-receptor
cortisol production earlier, and we found an intriguing mecha-
nism of action. Production of cortisol was remarkably inhibited
by the tea ﬂavanol, while the individual activities of the protein
components of the luminal cortisone reducing machinery
(G6PT-H6PD-11βHSD1) were unaffected. It turned out that
EGCG treatment causes the oxidation of luminal NADPH to
NADP+ via an enzymatic reaction, yet the enzymes involved
remain to be identiﬁed. This redox shift in the intravesicular
NADPH:NADP+ pool leads to an indirect inhibition of 11βHSD1
mediated cortisol production at a substrate level [12].
The phenomenon called “French paradox” was ﬁrst pub-
lished as a result of an epidemiologic study in 1992 [34], and
since then it has got a wide scientiﬁc publicity. Brieﬂy, it refers
to the surprisingly low mortality rate from coronary heart dis-
ease (CHD) in France despite elevated risk factors, such as high
serum cholesterol level, blood pressure, body-mass index and
rate of smoking [35]. The most widely accepted explanation for
the “French paradox” is the regular consumption of the poly-
phenol resveratrol. Inhibitory effect of resveratrol on 11βHSD1
in microsomes prepared from 3 T3-L1-derived adipocytes, rat
mesenteric and hepatic tissue has been reported earlier but the
exact molecular target remained to be elucidated [36]. The aim
of the present study was to reveal if resveratrol shares the
mechanism of action with EGCG and whether it also interferes
with the cofactor regeneration in the cortisol producing
machinery of the ER.
Administration of resveratrol caused a massive inhibition of
cortisol production in liver microsomes in a concentration-
dependent manner, which was comparable with the effect of
EGCG. However, unlike EGCG, resveratrol did not cause a sig-
niﬁcant redox shift in the luminal NADPH-NADP+ pool, that is,
the NADPH level, which drops upon EGCG treatment, was not
affected by the addition of resveratrol. The hindered G6P-
driven cortisol production in case of resveratrol was not due to
a competition for the cofactor but to a direct enzyme inhibition.
11βHSD1 enzyme activity was measured in two ways. The one
based on ﬂuorescent detection of NADPH was carried out using
high NADP+ concentration for technical reasons, while the one
employing HPLC detection of cortisone and cortisol allowed to
apply physiological cofactor levels. Data obtained using either
method demonstrated that resveratrol acts as a potent inhibitor
of 11βHSD1.
Since several molecular targets of resveratrol were identi-
ﬁed, the substance retrieved attention as a possible agent
against numerous diseases. Clinical signiﬁcance was examined
in a number of studies against type 2 diabetes mellitus, obesity,
skin disorders, different types of cancer, neurodegenerative, or
cardiovascular diseases. However, no general conclusion can
be drawn about the safety range and therapeutic effectiveness,
as the consequences are sometimes contradictory, data on cap-
sule versus food form consumption is conﬂicting and there are
uncertain effects of long term dosing. [14,37,38] Our results
show a novel molecular mechanism, however, inhibition of the
cortisone reducing machinery of the ER is only effective in an
early stage of the metabolic syndrome, as the importance of
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pre-receptor cortisol activation is diminishing in parallel with
the development of the disease. This highlights resveratrol,
along with EGCG as an important preventive agent. Unfortu-
nately, there are only a few clinical trials on preventive effects,
because long-term treatment and follow-up on numerous
healthy individuals were needed, with a given constant dose of
resveratrol. As the two mentioned natural polyphenols share
the same effect via separate modes of action, a combinational
treatment might result in additional efﬁcacy without
compromising tolerability.
Regardless of the exact molecular mechanism, repression
of prereceptor cortisol production clearly contributes to the
beneﬁcial health effects of both EGCG and resveratrol once con-
sumed regularly. Our ﬁndings suggest that depletion of micro-
somal NADPH is not a general polyphenol effect, and they
further support that the EGCG-induced NADPH oxidation is due
to a speciﬁc enzyme activity, which apparently fails to utilize
resveratrol.
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